WO2007011367A2 - Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16s ribosomal rna gene and identification of bacterial species by amplicon sequencing - Google Patents
Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16s ribosomal rna gene and identification of bacterial species by amplicon sequencing Download PDFInfo
- Publication number
- WO2007011367A2 WO2007011367A2 PCT/US2005/029296 US2005029296W WO2007011367A2 WO 2007011367 A2 WO2007011367 A2 WO 2007011367A2 US 2005029296 W US2005029296 W US 2005029296W WO 2007011367 A2 WO2007011367 A2 WO 2007011367A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- primer
- class
- pcr
- primers
- bacteria
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Definitions
- the present invention relates to the field of PCR methods, and specific primers therefore, as well as their use in the identification of any type of bacteria, and in particular RNA forms of bacteria.
- biological fluids for therapeutic human application such as plasmas, albumin, live vaccines, stem cells requires that they are absolutely devoid of bacterial contamination. It has been found that filtering, and possibly other traditional methods, may fail to eliminate all forms of organisms, leading to possible contamination or experimental artifacts.
- Devices are also provided for the in vitro detection of mycoplasmas in biological fluid by means of a reagent which is specific for the mycoplasma group without being specific for particular species within said group.
- Devices for testing mycoplasma sensitivity to antibiotics are also described.
- 20030134343 ; 20030134310; 20030134301; 20030134295; 20030134293; 20030134275; 20030131377; 20030131375; 20030129746; 20030129724; 20030129702; 20030129687; 20030129667; 20030129631; 20030129599; 20030129589; 20030129577; 20030129202; 20030125539; 20030125524; 20030125269; 20030125258; 20030125248; 20030124673; and 20030124613.
- the present invention allows improved detection of such bacterial contaminants, including unconventional forms such as filtering forms (nanoforms), nanobacteria, and L-forms.
- MOLL primers have been designed initially to detect mollicutes (mycoplasma) species based on the conserved regions of the 16s ribosomal RNA gene. In fact they can also detect gram positive bacteria
- BACT primers will detect gram positive and gram negative bacteria.
- the sequence of MOLL primers is included in the degenerated sequence of the BACT primers.
- Bact Outer Primer (antisense) CCCGRGAACGTATTCACSG
- Bact Inner Primer (sense) CCCGRGAGGCWGCAGTRRGGAAT
- the GNEG set of primers is specific of gram negative bacteria. It differs from the Moll 16 out S by a single nucleotide 1) Gneg Outer Primer (sense) (RAYGGGTGAGTAAYGYMT),
- the present invention therefore provides a method for identifying an RNA form of a bacteria, comprising reverse transcribing RNA material; conducting PCR using primers for a first highly conserved genetic sequence generic of the bacteria; conducting nested PCR using primers for a second highly conserved genetic sequence within the first amplified genetic sequence of the bacteria; and identifying the bacteria based on unconserved amplified sequences linked to the conserved sequences.
- Nanoforms are a stable, low metabolic rate form of bacteria, which may be related to pathology, which have characteristic DNA which is generally undetectable by PCR or nested PCR. However, these organisms do have characteristic RNA, and therefore these can be detected by nested RT-PCR. Likewise, because these are now detectable according to the present invention, it is therefore possible to monitor and optimize treatments directed toward clearing these from infected subjects.
- Nanoforms are involved in human pathology, and further that these low metabolic organisms are involved in a constellation of chronic human diseases. Further, it is believed that some of these Nanoforms may be subcellular, that is, incomplete, and therefore may require association with other Nanoform, or other organisms or cells, for replication or reconstitution as a complete DNA bacterial form. Preliminary evidence suggests that the genetic material within a single Nanoforms is insufficient to reconstitute the entirety of a related bacterial (DNA) form, and therefore that multiple Nanoforms may be required in order to be self- replicating for the complete organism.
- DNA related bacterial
- Nanofoms may infect a single cell, together constituting a complete genome for the associated DNA bacteria.
- Reverse transcriptase activity for example, due to retroviruses, endogenous retroviral sequences, DNA pol I activity, etc., may be sufficiently active to generate the bacterial genome.
- Nanoforms may be biologically associated with retroviruses, such as HIV, which would therefore increase their likelihood of replication, since they would then carry their own reverse transcriptase, and potentially account for replication of sub-cellular fragments.
- retroviruses such as HIV
- the retroviruses may be passengers within the Nanoforms, and the Nanoforms represent an infectious particle for the virus.
- Nanoforms retain conserved sequences of 16S rRNA, and therefore may be targeted on this basis, for example by tetracycline analog antibiotics, especially administered over extended durations.
- oligonucleotide primers used were:
- Expected lengths of amplicons are -1,200 bp and -450 bp with the outer and inner primers, respectively.
- the primers employed were formulated as equal amounts of each primer within the class identified by the sequence.
- Cell line supernatants 400 ⁇ l
- human plasma 200-400 ⁇ l
- human peripheral blood mononuclear cells PBMC, 3-10 millions cells
- lOmMTris pH7.4, 1OmM EDTA, 15OmM NaCl, 0.4% SDS, and lO ⁇ g Proteinase K at 60°C for 1 h.
- Nucleic samples were extracted three times with one volume of phenol/chloroform and one time with chloroform and precipitated by addition of 1/10 volume of 3M sodium acetate and two volumes of ethanol at -60°C for 1 h. Samples were centrifuged 30 min. and the nucleic acid pellets were washed with 70% cold ethanol and solubilized in 10 mM Tris-HCI, pH 8.0. These preparations were stored at -6O 0 C.
- PCR reaction mix (50 ⁇ l) consisted of 5mM MgCl2, 5OmM Tris, pH 8.0, 15mM (NH4)2SO4, lOmM B-Mercaptoethanol, 500 ⁇ M dATP, dCTP, dGTP, and DTTP, 0.025% BSA, l ⁇ M of each outer primer, 1 U Taq polymerase (Roche Molecular biochemicals, Laval, Canada), and 5-10 ⁇ l nucleic acid sample.
- the denaturation, annealing, and elongation temperatures and times used were 95°C for 30 s, 42 0 C for 30 s, and 78°C for 2 m, respectively, for 42 cycles.
- the products were kept at 78°C for 10 m.
- One ⁇ l of the PCR product was subjected to a second round PCR with the set of inner primers. Denaturation, annealing, and elongation temperatures and times used were 95°C for 30 s, 47°C for 30 s, and 78°C for 1 m, respectively, for 42 cycles, followed by a single incubation at 78 0 C for 10 m.
- lO ⁇ l of PCR product was analyzed by gel electrophoresis using 1.5% agarose, stained with ethidium bromide, visualized under ultraviolet light and photographed. Visible bands with appropriate size were cut and sequenced using the inner primers (DNA Landmarks, St-Jean sur Ie Richelieu, Canada). Sequence homology search was performed using the BLAST program of the NTH web site.
- RT-PCR reaction mix 50 ⁇ l was composed of 5mM MgCl2, 50 mM
- Tris pH 8.0, 15 mM (NH4)2SO4, 10 mM B-Mercaptoethanol, 500 ⁇ M dATP, dCTP, dGTP, and
- DTTP 0.025% BSA, l ⁇ M of each outer primer, and Titan enzyme mix (Roche Molecular biochemicals, Laval, Canada), and 5 ⁇ l nucleic acid sample.
- the reverse transcription step was performed at 42°C for 30 m.
- the first and second rounds PCR were performed as described above.
- Second round PCR (nested-PCR): all amplicon ( ⁇ 450bp) sequences related to bacterial 16S ribosomal RNA gene.
- RNA sequences such as the 16S rRNA
- PCR polymerase chain reaction
- RT-PCR reverse transcriptase PCR
- the present invention therefore provides a sensitive and specific method for detecting bacterial forms, which may be called “Nanoforms", even when traditional methods fail. This therefore allows diagnosis of pathogens previously unrecognized, and monitoring of treatment thereof.
Abstract
A method for identifying an RNA form of a bacteria, comprising reverse transcribing RNA material; conducting PCR using primers for a first highly conserved genetic sequence generic of the bacteria; conducting nested PCR using primers for a second highly conserved genetic sequence within the first genetic sequence of the bacteria; and identifying the bacteria based on unconserved amplified sequences linked to the conserved sequences.
Description
SENSITIVE DETECTION OF BACTERIA
BY IMPROVED NESTED POLYMERASE CHAIN REACTION
TARGETING THE 16S RIBOSOMAL RNA GENE
AND H)ENTEFICATION OF BACTERIAL SPECEES
BY AMPLICON SEQUENCING
FEELD OF THE INVENTION
The present invention relates to the field of PCR methods, and specific primers therefore, as well as their use in the identification of any type of bacteria, and in particular RNA forms of bacteria.
BACKGROUND OF THE INVENTION
The use of biological fluids for therapeutic human application such as plasmas, albumin, live vaccines, stem cells requires that they are absolutely devoid of bacterial contamination. It has been found that filtering, and possibly other traditional methods, may fail to eliminate all forms of organisms, leading to possible contamination or experimental artifacts.
It is believed that certain pathologies are associated with bacteria or bacterial forms which are difficult to detect, and which may pass through nano-porous barriers. This leads to possible errors in diagnosis or causation, and which may lead to erroneous treatment and impede prevention.
See, Hopert, Anne, UphofF, Cord C, Wirth, Manfred, Hauser, Hansjorg, and Drexler, Hans G., "Specificity and sensitivity of Polymerase Chain Reaction (PCR) in comparison with other methods for the detection of mycoplasma contamination in cell lines", J. Immunological Methods, 164(1993):91-100, expressly incorporated herein by reference.
Kajander, E.O., et al., "Comparison of Staphylococci and novel Bacteria-Like Particles from blood", ZbI. Bakt. Suppl. 26, 1994, expressly incorporated herein by reference.
Akerman, Kari K., "Scanning Electron Microscopy of Nanobacteria - Novel Biofϊlm Producing Organisms in Blood", Scanning Vol. 15, Suppl. Ill (1993), expressly incorporated
herein by reference.
expressly incorporated herein by reference.
Cifticioglu, Neva, et al., "Apoptotic effect of nanobacteria on cultured mammalian cells", MoI. Biol. Cell. Suppl., Vol. 7 (1996):517a
Cifticioglu, Neva, et al., "A new potential threat in antigen and antibody products: Nanobacteria", Vaccines 97, Brown et al. Ed., Cold Spring Harbor Laboratory Press, New York, 1997, expressly incorporated herein by reference.
Baseman, Joel B., et al., "Mycoplasmas: Sophisticated, Reemerging, and Burdened by their Notoriety", EID Vol. 3, N° 1 www, cdc.gov/ncidod/EID/vol3 no l/baseman,htm. expressly incorporated herein by reference.
Relman, David A., "Detection and Identification of Previously Unrecognized Microbial
Pathogens", EID Vol. 4, N° 3 www.cdc.gov/ncidod/EID/vol4no3/relman.htm. expressly incorporated herein by reference.
Mattman, Lida H., Cell Wall Deficient Forms-Stealth Pathogens, 2nd Ed., CRC Press (1993), expressly incorporated herein by reference.
U.S. Pat. No. 5,688,646, expressly incorporated herein by reference, describes novel mycoplasmas which are prominent in patients who are thought to be suffering from AIDS.
Devices are also provided for the in vitro detection of mycoplasmas in biological fluid by means of a reagent which is specific for the mycoplasma group without being specific for particular species within said group. Devices for testing mycoplasma sensitivity to antibiotics are also described.
See the following U.S. Patents and Published Patent Applications, each of which and cited references is expressly incorporated herein by reference in their entirety: 6,562,611; 6,558,902; 6,555,357; 6,555,338; 6,537,774; 6,492,113; 6,489,139; 6,489,110; 6,458,572; 6,458,535; 6,448,037; 6,432,703; 6,410,286; 6,399,343; 6,372,424; 6,361,965; 6,353,093; 6,350,600; 6,348,582; 6,348,328; 6,348,314; 6,346,397; 6,340,564; 6,331,411;
6,326,172; 6,312,932; 6,309,866; 6,303,771; 6,294,652; 6,294,357; 6,287,807; 6,287,804;
6,277,595; 6,274,719; 6,274,361; 6,270,762; 6,268,177; 6,261,802; 6,261,769; 6,255,075;
6,251,631; 6,251,629; 6,248,721; 6,245,891; 6,245,542; 6,238,900; 6,238,887; 6,238,882;
6,228,625; 6,228,584; 6,210,880; 6,204,014; 6,197,549; 6,197,300; 6,194,170; 6,190,881; 6,168,797; 6,165,992; 6,165,991; 6,165,764; 6,162,619; 6,162,618; 6,156,537; 6,146,863;
6,146,846; 6,140,079; 6,140,061; 6,111,074; 6,110,723; 6,110,685; 6,090,543; 6,060,294;
6,001,567; 5,994,111; 5,985,557; 5,882,643; 5,851,764; 5,843,669; 5,843,654; 5,795,976;
5,789,217; 5,786,197; 5,776,750; 5,763,246; 5,750,387; 5,688,646; 6,562,957; 6,545,140;
6,531,148; 6,495,661; 6,475,990; 6,451,601; 6,403,564; 6,399,373; 6,368,600; 6,339,151; 6,277,830; 6,258,778; 6,248,329; 6,245,750; 6,022,687; 6,593,086; 6,583,266; 6,573,068;
6,569,647; 6,562,611; 6,558,953; 6,558,909; 6,558,905; 6,558,902; 6,555,357; 6,548,633;
6,531,648; 6,524,795; 6,521,426; 6,518,020; 6,503,747; 6,495,325; 6,458,584; 6,458,535;
6,444,876; 6,436,399; 6,432,649; 6,423,499; 6,403,093; 6,399,307; 6,387,617; 6,372,424;
6,348,314; 6,329,138; 6,312,922; 6,312,903; 6,306,653; 6,300,091; 6,300,072; 6,287,779; 6,268,142; 6,261,773; 6,252,130; 6,251,607; 6,248,519; 6,221,582; 6,214,982; 6,214,548;
6,194,145; 6,180,339; 6,103,468; 6,090,543; 6,033,858; 6,025,132; 6,001,567; 6,001,564;
5,994,066; 5,985,557; 5,976,805; 5,958,693; 5,948,888; 5,948,634; 5,942,391; 5,939,262;
5,922,538; 5,919,625; 5,912,117; 5,907,085; 5,876,924; 5,843,669; 5,830,670; 5,795,976;
5,763,169; 5,747,257; 5,744,306; 5,734,086; 5,707,802; 5,693,467; 5,688,669; 5,677,124; 5,660,981; 5,658,749; 5,656,740; 5,643,723; 5,593,836; 5,589,570; 5,518,901; 5,310,874;
20030124545; 20030118992; 20030108873; 20030082614; 20030065156; 20030059771;
20030054338; 20030044864; 20030044796; 20030027286; 20030017532; 20020162123;
20020160447; 20020150963; 20020146790; 20020146751; 20020128437; 20020127596;
20020123047; 20020120116; 20020119520; 20020119510; 20020119454; 20020115075; 20020106776; 20020102700; 20020098544; 20020091237; 20020082234; 20020058799;
20020052472; 20020048789; 20020025516; 20020004581; 20020004580; 20010027183;
20010023064; 20010020010; 20010016334; 20010014670; 20010010912; 20030145347;
20030144490; 20030144234; 20030143684; 20030143671; 20030143618; 20030143600;
20030143593; 20030143577; 20030143553; 20030143537; 20030143534; 20030143531; 20030143241; 20030143219; 20030143202; 20030139590; 20030138925; 20030138854;
20030138816; 20030138803; 20030138798; 20030138783; 20030138772; 20030135879;
20030134343; 20030134310; 20030134301; 20030134295; 20030134293; 20030134275;
20030131377; 20030131375; 20030129746; 20030129724; 20030129702; 20030129687; 20030129667; 20030129631; 20030129599; 20030129589; 20030129577; 20030129202; 20030125539; 20030125524; 20030125269; 20030125258; 20030125248; 20030124673; and 20030124613.
SUMMARY OF THE INVENTION
The present invention allows improved detection of such bacterial contaminants, including unconventional forms such as filtering forms (nanoforms), nanobacteria, and L-forms.
Its principal applications are the:
Detection of very low levels of mycoplasma contamination of cell lines and biological fluids
Identification of latent bacterial infections in various pathologies - Detection of live forms passing through filters having a pore size of between 100 and
20nm Direct detection of RNA-containing subunits of bacteria.
Different primers have been designed: - MOLL primers have been designed initially to detect mollicutes (mycoplasma) species based on the conserved regions of the 16s ribosomal RNA gene. In fact they can also detect gram positive bacteria
1) Moll Outer Primer (sense) (AAYGGGTGAGTAACACGT),
2) Moll Outer Primer (antisense) (CCCGAGAACGTATTCACCG) 3) Moll Inner Primer (sense) (CTACGGGAGGCAGCAGTA)
4) Moll Inner Primer (antisense) (GTATCTAATCCTRTTTGCTCCCCA) BACT primers will detect gram positive and gram negative bacteria. The sequence of MOLL primers is included in the degenerated sequence of the BACT primers. 1) Bact Outer Primer (antisense) (CCCGRGAACGTATTCACSG), 2) Bact Inner Primer (sense) (CTACGGGAGGCWGCAGTRRGGAAT),
3) Bact Inner Primer (antisense) (WGGGTATCTAATCCTRTTTGMTCCCCW)
The GNEG set of primers is specific of gram negative bacteria. It differs from the Moll 16 out S by a single nucleotide 1) Gneg Outer Primer (sense) (RAYGGGTGAGTAAYGYMT),
The present invention therefore provides a method for identifying an RNA form of a bacteria, comprising reverse transcribing RNA material; conducting PCR using primers for a first highly conserved genetic sequence generic of the bacteria; conducting nested PCR using primers for a second highly conserved genetic sequence within the first amplified genetic sequence of the bacteria; and identifying the bacteria based on unconserved amplified sequences linked to the conserved sequences.
It is believed that the Nanoforms are a stable, low metabolic rate form of bacteria, which may be related to pathology, which have characteristic DNA which is generally undetectable by PCR or nested PCR. However, these organisms do have characteristic RNA, and therefore these can be detected by nested RT-PCR. Likewise, because these are now detectable according to the present invention, it is therefore possible to monitor and optimize treatments directed toward clearing these from infected subjects.
It is believed that Nanoforms are involved in human pathology, and further that these low metabolic organisms are involved in a constellation of chronic human diseases. Further, it is believed that some of these Nanoforms may be subcellular, that is, incomplete, and therefore may require association with other Nanoform, or other organisms or cells, for replication or reconstitution as a complete DNA bacterial form. Preliminary evidence suggests that the genetic material within a single Nanoforms is insufficient to reconstitute the entirety of a related bacterial (DNA) form, and therefore that multiple Nanoforms may be required in order to be self- replicating for the complete organism.
For example, multiple Nanofoms may infect a single cell, together constituting a complete genome for the associated DNA bacteria. Reverse transcriptase activity, for example, due to retroviruses, endogenous retroviral sequences, DNA pol I activity, etc., may be sufficiently active to generate the bacterial genome.
These Nanoforms may be biologically associated with retroviruses, such as HIV, which would therefore increase their likelihood of replication, since they would then carry their own reverse transcriptase, and potentially account for replication of sub-cellular fragments. The
retroviruses may be passengers within the Nanoforms, and the Nanoforms represent an infectious particle for the virus.
The present invention reveals that the Nanoforms retain conserved sequences of 16S rRNA, and therefore may be targeted on this basis, for example by tetracycline analog antibiotics, especially administered over extended durations.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Material and methods
Oligonucleotide primers.
The oligonucleotide primers used were:
1) Moll Outer Primer (sense) (AAYGGGTGAGTAACACGT), 2) Gneg Outer Primer (sense) (RAYGGGTGAGT AAYGYMT),
3) Bact Outer Primer (antisense) (CCCGRGAACGTATTCACSG),
4) Bact Inner Primer (sense) (CTACGGGAGGCWGCAGTRRGGAAT), and
5) Bact Inner Primer (antisense) (WGGGTATCTAATCCTRTTTGMTCCCCW) where R= G or A, S= G or C, W = A or T, M = A or C, and Y = T or C.
Expected lengths of amplicons are -1,200 bp and -450 bp with the outer and inner primers, respectively. The primers employed were formulated as equal amounts of each primer within the class identified by the sequence.
Nucleic acid preparation and PCR/RT-PCR.
Cell line supernatants (400 μl), human plasma (200-400μl) and human peripheral blood mononuclear cells (PBMC, 3-10 millions cells) were lyzed with lOmMTris, pH7.4, 1OmM EDTA, 15OmM NaCl, 0.4% SDS, and lOμg Proteinase K at 60°C for 1 h. Nucleic samples were extracted three times with one volume of phenol/chloroform and one time with chloroform and precipitated by addition of 1/10 volume of 3M sodium acetate and two volumes of ethanol at -60°C for 1 h. Samples were centrifuged 30 min. and the nucleic acid pellets were washed with 70% cold ethanol and solubilized in 10 mM Tris-HCI, pH 8.0. These preparations were stored at -6O0C.
PCR reaction mix (50μl) consisted of 5mM MgCl2, 5OmM Tris, pH 8.0, 15mM (NH4)2SO4, lOmM B-Mercaptoethanol, 500μM dATP, dCTP, dGTP, and DTTP, 0.025% BSA,
lμM of each outer primer, 1 U Taq polymerase (Roche Molecular biochemicals, Laval, Canada), and 5-10 μl nucleic acid sample. For the first round PCR, the denaturation, annealing, and elongation temperatures and times used were 95°C for 30 s, 420C for 30 s, and 78°C for 2 m, respectively, for 42 cycles. After the final cycle, the products were kept at 78°C for 10 m. One μl of the PCR product was subjected to a second round PCR with the set of inner primers. Denaturation, annealing, and elongation temperatures and times used were 95°C for 30 s, 47°C for 30 s, and 78°C for 1 m, respectively, for 42 cycles, followed by a single incubation at 780C for 10 m. After the first and second round PCR, lOμl of PCR product was analyzed by gel electrophoresis using 1.5% agarose, stained with ethidium bromide, visualized under ultraviolet light and photographed. Visible bands with appropriate size were cut and sequenced using the inner primers (DNA Landmarks, St-Jean sur Ie Richelieu, Canada). Sequence homology search was performed using the BLAST program of the NTH web site.
Samples negative for the appropriate band by PCR were subjected to a first round RT-PCR followed by a second round PCR. RT-PCR reaction mix (50μl) consisted of 5mM MgCl2, 50 mM
Tris, pH 8.0, 15 mM (NH4)2SO4, 10 mM B-Mercaptoethanol, 500μM dATP, dCTP, dGTP, and
DTTP, 0.025% BSA, lμM of each outer primer, and Titan enzyme mix (Roche Molecular biochemicals, Laval, Canada), and 5 μl nucleic acid sample. The reverse transcription step was performed at 42°C for 30 m. The first and second rounds PCR were performed as described above.
The precautions addressed elsewhere (Kwok and Higuchi, 1989) were followed to minimize the risk of false-positive results caused by the carry-over of previously amplified DNA. For example, extraction of nucleic acids and preparation of PCR/RT-PCR mix were performed under a sterile flow bench, only aliquoted reagents and filter tips were used, and negative controls were incorporated into each run.
Results
All Samples:
First round PCR / RT-PCR: no detection of expected amplicon (~l,200bp).
Second round PCR (nested-PCR): all amplicon (~450bp) sequences related to bacterial 16S ribosomal RNA gene.
Patients' lymphocytes (18 samples):
No 450bp amplicon detected by nested-PCR from first round PCR.
All samples positive (450bp) by nested-PCR from RT-PCR.
Therefore, bacteria are in an "RNA state", and are referred to herein as "Nanoforms".
Samples of Patients' Plasma:
11 samples/12 positive for 450bp amplicon by nested-PCR from first round PCR.
Discussion
Cell wall deficient pathogenic microorganisms, which may be mycoplasma, so-called L- forms, or potentially other types, are difficult to detect. Therefore, their involvement in pathology may be vastly under-reported.
It has been found, however, that these organisms have a well-conserved RNA sequences, such as the 16S rRNA, even when corresponding DNA or RNA is undetectable by a traditional polymerase chain reaction (PCR) or reverse transcriptase PCR (RT-PCR) method, which may be detected by nested RT-PCR amplification, using primers according to the present invention.
The present invention therefore provides a sensitive and specific method for detecting bacterial forms, which may be called "Nanoforms", even when traditional methods fail. This therefore allows diagnosis of pathogens previously unrecognized, and monitoring of treatment thereof.
What is claimed is:
Claims
1. A method for amplifying genetic sequences, comprising the steps of:
(1) first, reverse transcribing RNA to DNA, and conducting PCR using at least one outer primer having a sequence within the class: (AAYGGGTGAGTAACACGT) for Gram positive bacteria or,
(RAYGGGTGAGTAAYGYMT) for Gram negative bacteria, and at least one primer having a sequence within the class: (CCCGRGAACGTATTCACSG),
(2) second, conducting nested PCR, using inner primers, comprising at least one primer having a sequence within the class:
(CTACGGGAGGCWGCAGTRRGGAAT), and at least one primer having a sequence within the class: (WGGGTATCTAATCCTRTTTGMTCCCCW), wherein R= G or A, S= G or C, W = A or T, M = A or C, and Y = T or C.
2. The method according to claim 1 further comprising the step of identifying an organism corresponding to an amplicon resulting from said nested PCR step.
3. The method according to claim 1, wherein said PCR steps employ all primers having sequences within the specified classes, except optionally excluding primers within either the Gram positive primer or Gram negative primer classes.
4. A method for identifying an organism, comprising: (a) reverse transcribing RNA material to DNA; (b) conducting PCR using sense and antisense primers for a first highly conserved genetic sequence generic for the class of organism;
(c) conducting nested PCR using sense and antisense primers for a second highly conserved genetic sequence, within the first highly conserved genetic sequence; and
(d) identifying the organism based on unconserved amplified sequences linked to the conserved sequences.
5. The method according to claim 4, wherein said first and second highly conserved genetic sequences each comprise a part of a 16S ribosomal KNA sequence.
6. The method according to claim 4, wherein at least one of the primers are part of a degenerate set, further comprising the step of employing a plurality of primers within the class definition of the degenerate set.
7. A kit, comprising a unit amount of each of the following combinations of primer sequences, substantially absent interfering DNA primer sequences, sufficient for a PCR identification of a bacteria in a biological sample:
(a) at least one of:
(AAYGGGTGAGTAACACGT) and (RAYGGGTGAGT AAYGYMT), and (CCCGRGAACGTATTCACSG); and
(b) (CTACGGGAGGCWGCAGTRRGGAAT), and (WGGGTATCTAATCCTRTTTGMTCCCCW), wherein R= G or A, S= G or C, W = A or T, M = A or C, and Y = T or C.
8. The kit according to claim 7, wherein said component (a) further comprises a reverse transcriptase (RNA-dependent, DNA polymerase) activity, and deoxynucleotide triphosphates.
9. The kit according to claim 7, wherein said component (b) further comprises temperature resistant, DNA-dependent DNA polymersase activity, and deoxynucleotide triphosphates.
10. The kit according to claim 7, wherein at least one of said component (a) and (b) comprises 5mM MgC12, 50 mM Tris, pH 8.0, 15 mM (NH4)2SO4, 10 niM B-Mercaptoethanol, 500μM dATP, dCTP, dGTP, and dTTP, 0.025% BSA, lμM of each primer, a reverse transcriptase (RNA dependent DNA polymerase) activity, and a temperature resistant, DNA- dependent DNA polymerase activity.
11. The kit according to claim 7, wherein said component (a) comprises: all primer sequences falling within the class of at least one of: (AAYGGGTGAGTAACACGT) and (RAYGGGTGAGTAAYGYMT); and all primer sequences falling within the class: (CCCGRGAACGTATTCACSG).
12. The kit according to claim 11, wherein said component (b) comprises: all primer sequences falling within the class:
(CTACGGGAGGCWGCAGTRRGGAAT); and all primer sequences falling within the class:
(WGGGTATCTAATCCTRTTTGMTCCCCW).
13. The kit according to claim 17, wherein said component (b) comprises all primer sequences falling within the class:
(CTACGGGAGGCWGCAGTRRGGAAT); and all primer sequences falling within the class: (WGGGTATCTAATCCTRTTTGMTCCCCW).
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60312004P | 2004-08-20 | 2004-08-20 | |
US60/603,120 | 2004-08-20 | ||
US11/204,854 | 2005-08-16 | ||
US11/204,854 US7309589B2 (en) | 2004-08-20 | 2005-08-16 | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007011367A2 true WO2007011367A2 (en) | 2007-01-25 |
WO2007011367A3 WO2007011367A3 (en) | 2007-11-15 |
Family
ID=36034487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/029296 WO2007011367A2 (en) | 2004-08-20 | 2005-08-17 | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16s ribosomal rna gene and identification of bacterial species by amplicon sequencing |
Country Status (2)
Country | Link |
---|---|
US (2) | US7309589B2 (en) |
WO (1) | WO2007011367A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2342525A1 (en) * | 2008-06-02 | 2010-07-07 | Universidad De Vigo | Procedure for the genetic identification of the european centolla del atlantico (maja brachydactyla). (Machine-translation by Google Translate, not legally binding) |
ES2366289A1 (en) * | 2010-03-18 | 2011-10-19 | Universidad De Vigo | Procedure for the genetic identification of the european spices of the maja genero (cellulas). (Machine-translation by Google Translate, not legally binding) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7309589B2 (en) * | 2004-08-20 | 2007-12-18 | Vironix Llc | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
US8405379B1 (en) | 2008-09-18 | 2013-03-26 | Luc Montagnier | System and method for the analysis of DNA sequences in biological fluids |
EP2723903A4 (en) * | 2011-06-27 | 2015-02-18 | Gen Mills Inc | Detection and quantification of lactic acid producing bacteria in food products |
US10584370B2 (en) * | 2014-12-16 | 2020-03-10 | Soft Cell Biological Research, Llc | Screening for L-form bacteria |
CN114641302A (en) * | 2019-08-28 | 2022-06-17 | 污染源识别有限责任公司 | Rapid isolation and collection of microbial RNA from biological samples |
CN112941214B (en) * | 2021-03-29 | 2023-04-11 | 中国农业大学 | Primer group for gram-negative bacterium drug-resistant gene high-throughput amplicon sequencing and application |
CN113564269A (en) * | 2021-07-21 | 2021-10-29 | 翌圣生物科技(上海)股份有限公司 | Probe composition for preventing reverse transcription of bacterial conserved region and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077601A1 (en) * | 1999-04-15 | 2003-04-24 | Ebersole Richard C. | Nucleic acid fragments for the identification of dechlorinating bacteria |
Family Cites Families (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6027913A (en) * | 1988-01-28 | 2000-02-22 | Sommer; Steven S. | Nucleic acid amplification with direct sequencing |
US6455492B1 (en) * | 1988-06-17 | 2002-09-24 | Genelabs Technologies, Inc. | Hepatitis E virus vaccine and method |
US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
US5912117A (en) | 1990-03-07 | 1999-06-15 | Roche Molecular Systems, Inc. | Method for diagnosis of lyme disease |
US5677123A (en) * | 1990-05-18 | 1997-10-14 | Institut Pasteur | Mycoplasmas--agents for detecting and characterizing mycoplasmas in vitro |
US5851764A (en) | 1990-10-25 | 1998-12-22 | The Trustees Of Columbia University In The City Of New York | Human prostate tumor inducing gene-1 and uses thereof |
US5310874A (en) * | 1991-05-03 | 1994-05-10 | The Scripps Research Institute | Integrin α subunit cytoplasmic domain polypeptides and antibodies |
US5994069A (en) * | 1996-01-24 | 1999-11-30 | Third Wave Technologies, Inc. | Detection of nucleic acids by multiple sequential invasive cleavages |
US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
US6372424B1 (en) * | 1995-08-30 | 2002-04-16 | Third Wave Technologies, Inc | Rapid detection and identification of pathogens |
US6673616B1 (en) * | 1992-12-07 | 2004-01-06 | Third Wave Technologies, Inc. | Methods and compositions for characterizing nucleic acids |
US5843654A (en) | 1992-12-07 | 1998-12-01 | Third Wave Technologies, Inc. | Rapid detection of mutations in the p53 gene |
US5744306A (en) | 1993-04-19 | 1998-04-28 | Emory University | Methods for nucleic acid detection, sequencing, and cloning using exonuclease |
US5518901A (en) | 1993-04-19 | 1996-05-21 | Murtagh; James J. | Methods for adapting nucleic acid for detection, sequencing, and cloning using exonuclease |
US5593836A (en) | 1993-05-14 | 1997-01-14 | Niemiec; John T. | Primers and probes for detecting Pneumocystis carinii |
US5571711A (en) * | 1993-06-17 | 1996-11-05 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors |
NL9301957A (en) * | 1993-11-11 | 1995-06-01 | U Gene Research Bv | Method for identifying microorganisms, and useful tools. |
US5561064A (en) * | 1994-02-01 | 1996-10-01 | Vical Incorporated | Production of pharmaceutical-grade plasmid DNA |
US5658749A (en) | 1994-04-05 | 1997-08-19 | Corning Clinical Laboratories, Inc. | Method for processing mycobacteria |
WO1995030745A1 (en) | 1994-05-10 | 1995-11-16 | Cornell Research Foundation, Inc. | CYTOCHROME P4501pr GENE AND ITS USES |
US5643723A (en) | 1994-05-26 | 1997-07-01 | Roche Molecular Systems, Inc. | Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures and in clinical specimens |
US5660981A (en) | 1994-06-06 | 1997-08-26 | E. I. Du Pont De Nemours And Company | Selection of diagnostic genetic markers in microorganisms and use of a specific marker for detection of salmonella |
US5876924A (en) | 1994-06-22 | 1999-03-02 | Mount Sinai School Of Medicine | Nucleic acid amplification method hybridization signal amplification method (HSAM) |
US5942391A (en) | 1994-06-22 | 1999-08-24 | Mount Sinai School Of Medicine | Nucleic acid amplification method: ramification-extension amplification method (RAM) |
EP1088899A3 (en) | 1994-06-24 | 2001-05-02 | N.V. Innogenetics S.A. | Simultaneous detection, identification and differentiation of Eubacterial taxa using a hybridization assay |
US6001564A (en) | 1994-09-12 | 1999-12-14 | Infectio Diagnostic, Inc. | Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
JPH10507921A (en) | 1994-10-28 | 1998-08-04 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Polynucleic acid sequences for prokaryotic detection and identification |
CA2205964A1 (en) | 1994-11-29 | 1996-06-06 | Douglas A. Marchuk | Diagnosis of and therapy for hereditary haemorrhagic telangiectasia |
US5763169A (en) | 1995-01-13 | 1998-06-09 | Chiron Diagnostics Corporation | Nucleic acid probes for the detection and identification of fungi |
US6180339B1 (en) | 1995-01-13 | 2001-01-30 | Bayer Corporation | Nucleic acid probes for the detection and identification of fungi |
US5707802A (en) | 1995-01-13 | 1998-01-13 | Ciba Corning Diagnostics Corp. | Nucleic acid probes for the detection and identification of fungi |
US6077692A (en) * | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
DE19515891C2 (en) | 1995-04-29 | 1999-10-28 | Roche Diagnostics Gmbh | Genus and species-specific identification of Legionella |
US5693467A (en) | 1995-05-19 | 1997-12-02 | The American Type Culture Collection | Mycoplasma polymerase chain reaction testing system using a set of mixed and single sequence primers |
US5795976A (en) | 1995-08-08 | 1998-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of nucleic acid heteroduplex molecules by denaturing high-performance liquid chromatography and methods for comparative sequencing |
US5994066A (en) | 1995-09-11 | 1999-11-30 | Infectio Diagnostic, Inc. | Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories |
US6252130B1 (en) | 1995-11-13 | 2001-06-26 | University Of Rochester | Production of somatic mosaicism in mammals using a recombinatorial substrate |
ZA9610721B (en) | 1995-12-21 | 1998-06-19 | Cornell Res Foundation Inc | Grapevine leafroll virus proteins and their uses. |
US5888736A (en) * | 1995-12-22 | 1999-03-30 | Visible Genetics, Inc. | Method, compositions and kit for detection and identification of microorganisms |
US5789217A (en) * | 1997-01-17 | 1998-08-04 | Smithkline Beecham P.L.C. | DNA encoding asparaginyl tRNA synthetase from staphylococcus aureus |
EP0785270A1 (en) | 1996-01-19 | 1997-07-23 | Smithkline Beecham Plc | Staphylococcus aureus Seryl-tRNA synthetase |
EP0815237A1 (en) | 1996-01-19 | 1998-01-07 | Smithkline Beecham Plc | Threonyl-trna synthetase of staphylococcus aureus |
GB9601069D0 (en) * | 1996-01-19 | 1996-03-20 | Smithkline Beecham Plc | Novel compounds |
JPH11502424A (en) | 1996-01-19 | 1999-03-02 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Staphylococcus aureus arginyl tRNA synthetase |
US5854067A (en) * | 1996-01-19 | 1998-12-29 | Board Of Regents, The University Of Texas System | Hexokinase inhibitors |
US5985557A (en) | 1996-01-24 | 1999-11-16 | Third Wave Technologies, Inc. | Invasive cleavage of nucleic acids |
EP0819167A4 (en) * | 1996-01-24 | 2002-06-12 | Synaptic Pharma Corp | Dna encoding galanin galr2 receptors and uses thereof |
US5747257A (en) | 1996-02-29 | 1998-05-05 | E. I. Du Pont De Nemours And Company | Genetic markers and methods for the detection of escherichia coli serotype-0157:H7 |
US6348328B1 (en) * | 1997-05-14 | 2002-02-19 | Smithkline Beecham Corporation | Compounds |
US5939262A (en) | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
US5677124A (en) | 1996-07-03 | 1997-10-14 | Ambion, Inc. | Ribonuclease resistant viral RNA standards |
US6107071A (en) * | 1996-09-24 | 2000-08-22 | Smithkline Beecham Corporation | Histidinol dehydrogenase |
US5922538A (en) | 1996-11-08 | 1999-07-13 | E.I. Du Pont De Nemours And Company | Genetic markers and methods for the detection of Listeria monocytogenes and Listeria spp |
US5786197A (en) | 1996-11-25 | 1998-07-28 | Smithkline Beecham Corporation | lep |
CA2273204C (en) * | 1996-11-29 | 2008-10-14 | Third Wave Technologies, Inc. | Fen-1 endonucleases, mixtures and cleavage methods |
US6214548B1 (en) | 1997-01-29 | 2001-04-10 | The United States Of America As Represented By The Secretary Of The Army | Diagnostic methods for Cyclospora |
US7105724B2 (en) * | 1997-04-04 | 2006-09-12 | Board Of Regents Of University Of Nebraska | Methods and materials for making and using transgenic dicamba-degrading organisms |
US6248721B1 (en) * | 1997-04-09 | 2001-06-19 | Lung-Ji Chang | Method of using mouse model for evaluation of HIV vaccines |
US6210880B1 (en) | 1997-09-19 | 2001-04-03 | Third Wave Technologies, Inc. | Polymorphism analysis by nucleic acid structure probing with structure-bridging oligonucleotides |
GB9711040D0 (en) | 1997-05-29 | 1997-07-23 | Duff Gordon W | Prediction of inflammatory disease |
US6165992A (en) | 1997-05-30 | 2000-12-26 | Smithkline Beecham Corporation | Histidine kinase |
US6165991A (en) | 1997-05-30 | 2000-12-26 | Smithkline Beecham Corporation | Sensor histidine kinase of Streptococcus pneumoniae |
US6238882B1 (en) * | 1997-07-01 | 2001-05-29 | Smithkline Beecham Corporation | GidA1 |
EP0892055A3 (en) * | 1997-07-01 | 2002-03-20 | Smithkline Beecham Corporation | GidB polypeptides from Staphylococcus aureus |
EP1007673B1 (en) * | 1997-07-30 | 2008-12-17 | Emory University | Novel bone mineralization proteins, dna, vectors, expression systems |
US6156537A (en) | 1997-08-12 | 2000-12-05 | Smithkline Beecham Corporation | Phospho-N-acetylmuramoyl-pentapeptide transferase of Streptococcus pneumoniae |
US6197300B1 (en) | 1997-08-12 | 2001-03-06 | Smithkline Beecham Corporation | ftsZ |
US6274361B1 (en) * | 1997-08-26 | 2001-08-14 | Smithkline Beecham Corporation | pth |
US6228584B1 (en) | 1997-09-02 | 2001-05-08 | Smithkline Beecham Corporation | DexB |
US6225087B1 (en) * | 1997-09-09 | 2001-05-01 | Smithkline Beecham Corporation | Response regulator |
US6287807B1 (en) * | 1997-09-25 | 2001-09-11 | Smithkline Beecham Corporation | MurF |
US6194170B1 (en) | 1997-09-25 | 2001-02-27 | Smithkline Beecham Corporation | MurF of Streptococcus pneumoniae |
US6146863A (en) | 1997-10-03 | 2000-11-14 | Smithkline Beecham Corporation | Staphylococcus aureus 3-hydroxyacyl-CoA dehydrogenase |
JP2002540758A (en) | 1997-10-03 | 2002-11-26 | スミスクライン・ビーチャム・コーポレイション | AMA |
US6238887B1 (en) * | 1997-10-03 | 2001-05-29 | Brigham & Women's Hospital | Ribosome recycling factor (FRR) of Staphylococcus aureus |
US6251629B1 (en) * | 1997-10-07 | 2001-06-26 | Smithkline Beecham Corporation | ABC transporter |
US6103468A (en) | 1997-10-07 | 2000-08-15 | Labatt Brewing Company Limited | Rapid two-stage polymerase chain reaction method for detection of lactic acid bacteria in beer |
US6331411B1 (en) * | 1997-10-14 | 2001-12-18 | Smithkline Beecham Corporation | TopA |
US6303771B1 (en) * | 1997-11-20 | 2001-10-16 | Smithkline Beecham Corporation | Pth |
US6930175B1 (en) * | 1997-12-12 | 2005-08-16 | The Johns Hopkins University School Of Medicine | Gene family with transformation modulating activity |
US6261802B1 (en) * | 1997-12-17 | 2001-07-17 | Smithkline Beecham Corporation | Ups (ugc) |
ATE343642T1 (en) * | 1998-01-23 | 2006-11-15 | Biomerieux Bv | EF-TU MRNA AS A MARKER FOR VIABLE BACTERIA |
EP1045897B1 (en) | 1998-01-23 | 2002-01-30 | Newbiotics Inc. | Enzyme catalyzed therapeutic agents |
US6448037B1 (en) * | 1998-02-20 | 2002-09-10 | Smithkline Beecham Corporation | PgsA |
US6248519B1 (en) | 1998-03-11 | 2001-06-19 | E & J Gallo Winery | Detection of fermentation-related microorganisms |
US6287804B1 (en) * | 1998-03-17 | 2001-09-11 | Smithkline Beecham Corporation | nrdG |
US6555338B1 (en) * | 1998-03-17 | 2003-04-29 | Smithkline Beecham Corporation | NrdF from Staphylococcus aureus |
JP4196236B2 (en) | 1998-03-17 | 2008-12-17 | 東洋紡績株式会社 | Nucleic acid amplification reagent and sequence-specific nucleic acid amplification method |
US6162619A (en) | 1998-03-26 | 2000-12-19 | Smithkline Beecham Corporation | Sensor histidine kinase of streptococcus pneumoniae |
EP0947525A1 (en) * | 1998-03-27 | 1999-10-06 | Innogenetics N.V. | Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue |
US6033858A (en) | 1998-03-30 | 2000-03-07 | Bastian; Frank O. | Detection of transmissible spongiform encephalopathies |
US6261769B1 (en) | 1998-03-31 | 2001-07-17 | The United States Of America As Represented By The Secretary Of Agriculture | Intergenic spacer target sequence for detecting and distinguishing Chlamydial species or strains |
US6162618A (en) * | 1998-04-10 | 2000-12-19 | Smithkline Beecham Corporation | 6-phosphogluconate dehydrogenase of Streptococcus pneumoniae |
US6274719B1 (en) * | 1998-04-24 | 2001-08-14 | Smithkline Beecham Corporation | Gcp |
US6146846A (en) | 1998-04-27 | 2000-11-14 | Smithkline Beecham Corporation | Primosome protein a of streptococcus pneumoniae |
US5976805A (en) | 1998-04-27 | 1999-11-02 | Becton Dickinson And Company | Neisseria gonorrhoeae specific DNA fragment--GC3 |
US6723564B2 (en) * | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
US6245891B1 (en) * | 1998-05-11 | 2001-06-12 | Smithkline Beecham Corporation | nusB polypeptides and polynucleotides and methods thereof |
US6248329B1 (en) | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US6190881B1 (en) | 1998-06-05 | 2001-02-20 | Smithkline Beecham Corporation | Ribonucleotide diphosphate reductase, nrdF, of streptococcus pneumoniae |
AU756785B2 (en) | 1998-07-13 | 2003-01-23 | University Of Southern California | Methods for accelerating bone and cartilage growth and repair |
US20030125269A1 (en) * | 1998-08-26 | 2003-07-03 | Ming Li | T-type calcium channel |
US6432703B1 (en) * | 1998-08-27 | 2002-08-13 | Smithkline Beecham Corporation | RATC from Streptococcus pneumoniae |
US6268177B1 (en) * | 1998-09-22 | 2001-07-31 | Smithkline Beecham Corporation | Isolated nucleic acid encoding nucleotide pyrophosphorylase |
US20030082614A1 (en) * | 2001-05-29 | 2003-05-01 | Sanjoy Biswas | Map |
US20030118992A1 (en) * | 1998-09-29 | 2003-06-26 | Warren Richard Lloyd | ABC transporter |
US6537774B1 (en) * | 1998-10-14 | 2003-03-25 | Smithkline Beecham Corporation | UPS (undecaprenyl diphosphate synthase |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
US6255075B1 (en) * | 1998-10-20 | 2001-07-03 | Smithkline Beecham Corporation | Bira |
US6110685A (en) * | 1998-10-28 | 2000-08-29 | Smithkline Beecham Corporation | infB |
US6228625B1 (en) | 1998-11-03 | 2001-05-08 | Smithkline Beecham Corporation | metK from Streptococcus pneumoniae |
US6165764A (en) | 1998-11-09 | 2000-12-26 | Smithkline Beecham Corporation | Polynucleotides encoding tRNA methyl transferases from Streptococcus pneumoniae |
US6361965B1 (en) * | 1998-11-12 | 2002-03-26 | Smithkline Beecham Corporation | YfiI pseudouridine synthase |
US6110723A (en) * | 1998-11-12 | 2000-08-29 | Smithkline Beecham Corporation | Yfii pseudouridine synthase |
US6204014B1 (en) | 1998-11-13 | 2001-03-20 | Smithkline Beecham Corporation | DnaB |
US6277595B1 (en) * | 1998-11-19 | 2001-08-21 | Smithkline Beecham Corporation | FabZ |
US6340564B1 (en) * | 1999-01-26 | 2002-01-22 | Smithkline Beecham Corporation | yhxB |
US6417342B1 (en) * | 1999-02-12 | 2002-07-09 | University Of Iowa Research Foundation | Macular degeneration diagnostics and therapeutics |
US6251631B1 (en) * | 1999-02-16 | 2001-06-26 | Smithkline Beecham Corporation | nadE from Streptococcus pneumoniae |
US20030125539A1 (en) * | 1999-02-22 | 2003-07-03 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
US6221660B1 (en) * | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
US6270762B1 (en) * | 1999-02-26 | 2001-08-07 | Smithkline Beecham Corporation | tdk |
JP2003500009A (en) * | 1999-03-01 | 2003-01-07 | ドクトル ファン ハーリンゲン ラボラトリウム ベー.フェー. | Microbial detection and quantification using amplification and restriction enzyme analysis |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
US6492113B1 (en) * | 1999-04-01 | 2002-12-10 | Immunosciences Lab, Inc., Calif. Corporation | Detection of Mycoplasma genus and species in patients with chronic fatigue syndrome and fibromyalgia |
US6897337B2 (en) * | 1999-04-09 | 2005-05-24 | Abbott Laboratories | Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor |
US6346397B1 (en) * | 1999-04-12 | 2002-02-12 | Smithkline Beecham Corportion | GyrA |
US20030138925A1 (en) * | 2000-04-13 | 2003-07-24 | Tim Keith | Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease |
DE19918141A1 (en) * | 1999-04-21 | 2000-10-26 | Boehringer Ingelheim Vetmed | Diagnosing transmissible spongiform encephalopathy, particularly before appearance of clinical symptoms, by detecting specific markers in blood cells |
US6245542B1 (en) * | 1999-05-06 | 2001-06-12 | Smithkline Beecham Corporation | tRNA methyltransferase from Streptococcus pneumoniae |
US6489139B1 (en) * | 1999-06-24 | 2002-12-03 | Smithkline Beecham Corporation | FabZ from Staphylococcus aureus |
US6168797B1 (en) | 1999-08-18 | 2001-01-02 | Smithkline Beecham Corporation | FabF |
US6294357B1 (en) * | 1999-08-31 | 2001-09-25 | Smithkline Beecham Corporation | FabF from Staphylococcus aureus |
EP1214402B1 (en) * | 1999-09-01 | 2005-05-18 | Monsanto Technology LLC | Plant regulatory sequences for selective control of gene expression |
US6300073B1 (en) * | 1999-10-01 | 2001-10-09 | Clontech Laboratories, Inc. | One step RT-PCR methods, enzyme mixes and kits for use in practicing the same |
US6541202B1 (en) * | 1999-10-13 | 2003-04-01 | Research & Development Institute, Inc. | Telomerase reverse transcriptase (TERT) genes from Candida albicans |
US6326172B1 (en) * | 1999-11-04 | 2001-12-04 | Smithkline Beecham Corp. | ytgP |
US20030134293A1 (en) * | 1999-11-16 | 2003-07-17 | Zhiping Liu | Method for rapid and accurate identification of microorganisms |
US6251607B1 (en) | 1999-12-09 | 2001-06-26 | National Science Council Of Republic Of China | PCR primers for the rapid and specific detection of Salmonella typhimurium |
FR2803599B1 (en) * | 2000-01-06 | 2004-11-19 | Inst Nat Sante Rech Med | NEW MUTATED HEPATITIS B VIRUS, ITS NUCLEIC AND PROTEIN CONSTITUENTS AND THEIR APPLICATIONS |
SE0000061D0 (en) * | 2000-01-10 | 2000-01-10 | Bjoern Herrmann | A method for detection of pathogenic organisms |
US6287779B1 (en) | 2000-01-20 | 2001-09-11 | E. & J. Gallo Winery | Detection of fermentation-related microorganisms |
US20020004224A1 (en) * | 2000-02-29 | 2002-01-10 | Sheppard Paul O. | Kunitz domain polypeptide zkun8 |
US20030129724A1 (en) * | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
DE60108950T2 (en) * | 2000-04-13 | 2006-02-23 | Millipore Corp., Billerica | METHOD AND APPARATUS FOR PLASMID RECOVERY USING ULTRAFILTRATION |
US6576423B2 (en) * | 2000-12-08 | 2003-06-10 | The Board Of Regents Of The University Of Nebraska | Specific mucin expression as a marker for pancreatic cancer |
US6756200B2 (en) * | 2001-01-26 | 2004-06-29 | The Johns Hopkins University School Of Medicine | Aberrantly methylated genes as markers of breast malignancy |
US7060434B2 (en) * | 2001-02-14 | 2006-06-13 | Council Of Scientific & Industrial Research | Probes for myctophid fish and a method for developing the same |
WO2002070728A2 (en) * | 2001-03-01 | 2002-09-12 | The Johns Hopkins University | Quantitative assay for the simultaneous detection and speciation of bacterial infections |
ATE376184T1 (en) * | 2001-03-09 | 2007-11-15 | Univ Oklahoma | EPITOPE EXAMINATION WITH HLA |
US7022475B2 (en) * | 2001-03-29 | 2006-04-04 | St. Jude Children's Research Hospital | Genotyping assay to predict CYP3A5 phenotype |
US20030134301A1 (en) * | 2001-07-27 | 2003-07-17 | Brooksbank Robert Alan | Identification and use of molecules implicated in pain |
US20030138803A1 (en) * | 2001-07-27 | 2003-07-24 | Brooksbank Robert Alan | Identification and use of molecules implicated in pain |
WO2003014348A1 (en) * | 2001-08-06 | 2003-02-20 | Monsanto Technology Llc | Dna molecules from maize and methods of use thereof |
US20030138816A1 (en) * | 2001-10-05 | 2003-07-24 | Institut National De La Sante Et De La Recherche Medicale | Methods and kits for diagnosing the occurrence or the phase of minimal change nephrotic syndrome (MCNS) in a human |
US20030143219A1 (en) * | 2001-10-09 | 2003-07-31 | Madison Edwin L | Nucleic acid molecules encoding a transmembrane serine protease 25, the encoded polypeptides and methods based thereon |
AU2002360388A1 (en) * | 2001-11-13 | 2003-05-26 | Phylos, Inc. | Cellular kinase targets and inhibitors, and methods for their use |
CA3066428C (en) * | 2001-11-13 | 2022-05-24 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
CA2469972A1 (en) * | 2001-12-20 | 2003-07-03 | Phenogene Therapeutiques Inc. | Bone polypeptide-1 |
US7932070B2 (en) * | 2001-12-21 | 2011-04-26 | Agilent Technologies, Inc. | High fidelity DNA polymerase compositions and uses therefor |
US6900017B2 (en) * | 2002-01-10 | 2005-05-31 | The Board Of Trustees Of The University Of Illinois | Human hematopoietic growth regulatory gene and uses |
GB0202252D0 (en) * | 2002-01-31 | 2002-03-20 | Oxford Biomedica Ltd | Anemia |
EP1371736B1 (en) * | 2002-06-04 | 2006-08-16 | Vitro Hellas S.A. | Highly sensitive nested PCR detection scheme for efficient multiplex detection of members of Vitivirus, Foveavirus and Closterovirus genus in grapevine |
US7309589B2 (en) * | 2004-08-20 | 2007-12-18 | Vironix Llc | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing |
-
2005
- 2005-08-16 US US11/204,854 patent/US7309589B2/en not_active Expired - Fee Related
- 2005-08-17 WO PCT/US2005/029296 patent/WO2007011367A2/en active Application Filing
-
2007
- 2007-12-10 US US11/953,738 patent/US20080213773A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030077601A1 (en) * | 1999-04-15 | 2003-04-24 | Ebersole Richard C. | Nucleic acid fragments for the identification of dechlorinating bacteria |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2342525A1 (en) * | 2008-06-02 | 2010-07-07 | Universidad De Vigo | Procedure for the genetic identification of the european centolla del atlantico (maja brachydactyla). (Machine-translation by Google Translate, not legally binding) |
ES2366289A1 (en) * | 2010-03-18 | 2011-10-19 | Universidad De Vigo | Procedure for the genetic identification of the european spices of the maja genero (cellulas). (Machine-translation by Google Translate, not legally binding) |
Also Published As
Publication number | Publication date |
---|---|
WO2007011367A3 (en) | 2007-11-15 |
US7309589B2 (en) | 2007-12-18 |
US20080213773A1 (en) | 2008-09-04 |
US20060057616A1 (en) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dragsted et al. | Comparison of culture and PCR for detection of Bordetella pertussis and Bordetella parapertussis under routine laboratory conditions | |
WO2007011367A2 (en) | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16s ribosomal rna gene and identification of bacterial species by amplicon sequencing | |
Maiwald | Broad‐range PCR for detection and identification of bacteria | |
Yang et al. | Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients | |
Schaeverbeke et al. | Systematic detection of mycoplasmas by culture and polymerase chain reaction (PCR) procedures in 209 synovial fluid samples. | |
Yang et al. | Rapid PCR-based diagnosis of septic arthritis by early Gram-type classification and pathogen identification | |
EP0979312B1 (en) | Nucleic acids for detecting aspergillus species | |
EP2419527B1 (en) | Method for the detection and characterization of a toxinogenic clostridium difficile strain | |
Kumar et al. | Rapid multiplex PCR assay for the simultaneous detection of the Brucella Genus, B. abortus, B. melitensis, and B. suis | |
Sune et al. | Optimization of 16S rRNA gene analysis for use in the diagnostic clinical microbiology service | |
CN116438299A (en) | CRISPR-based assays for detecting pathogens in samples | |
JPH11514522A (en) | Improved molecular detection method based on IS6110 of MYCOBACTERIUM TUBERCULOSIS | |
US20110287428A1 (en) | Neisseria gonorrhoeae detection | |
Ruiz-Fuentes et al. | Comparison of four DNA extraction methods for the detection of Mycobacterium leprae from Ziehl–Neelsen-stained microscopic slides | |
US20110287965A1 (en) | Methods and compositions to detect clostridium difficile | |
US20110200984A1 (en) | Using nucleic acids for clinical microbiology testing | |
CN110468223B (en) | Primer, probe, kit and method for detecting nucleic acid of mycoplasma pneumoniae and bauxiella based on dUTP/UNG method | |
US20130295557A1 (en) | Selective detection of haemophilus influenzae | |
Hizel et al. | Polymerase chain reaction in the diagnosis of invasive aspergillosis. | |
Nagdev et al. | Comparison of real-time PCR and conventional PCR assay using IS6110 region of Mycobacterium tuberculosis for efficient diagnosis of tuberculous meningitis and pulmonary tuberculosis | |
Meddeb et al. | Comparison between a broad-range real-time and a broad-range end-point PCR assays for the detection of bacterial 16S rRNA in clinical samples | |
Panning et al. | High throughput screening for spores and vegetative forms of pathogenic B. anthracis by an internally controlled real-time PCR assay with automated DNA preparation | |
CN111004855A (en) | Primer combination and kit for detecting staphylococcus aureus | |
Heininger et al. | Effect of comprehensive validation of the template isolation procedure on the reliability of bacteraemia detection by a 16S rRNA gene PCR | |
Boruń et al. | Detection of Mycobacterium tuberculosis in clinical samples using insertion sequences IS 6110 and IS990 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |